We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...
JMP Securities reiterated its Market Outperform rating on Protagonist Therapeutics (NASDAQ:PTGX) with a steady price target ...
Truist Securities reiterated its Buy rating and $60.00 price target for Protagonist Therapeutics (NASDAQ:PTGX) shares, which currently trade at $38.78 with a market capitalization of $2.3 billion. The ...
After hours: February 7 at 6:12:20 PM EST Loading Chart for VERA ...
Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) has earned a consensus rating of “Buy” from the nine ...
Bleakley Financial Group LLC cut its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 9.4% in the ...
PRAX Praxis Precision Medicines, Inc.
Our round-up of recent biotech financings is headed by a $250 million public offering for late clinical-stage biotech Vera Therapeutics, with an initial public offering (IPO) filed by CAR-T ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results